{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:50:14Z","timestamp":1790621414030,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s41669-023-00386-2","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T21:44:22Z","timestamp":1675979062000},"page":"243-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States"],"prefix":"10.1007","volume":"7","author":[{"given":"Rajiv","family":"Mallick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashad","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Van Stiphout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"issue":"8","key":"386_CR1","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","volume":"18","author":"C Bunschoten","year":"2019","unstructured":"Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18(8):784\u201394.","journal-title":"Lancet Neurol"},{"issue":"1","key":"386_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","volume":"73","author":"RS Laughlin","year":"2009","unstructured":"Laughlin RS, Dyck PJ, Melton LJ 3rd, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39\u201345.","journal-title":"Neurology"},{"issue":"1","key":"386_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1529-8027.2010.00251.x","volume":"15","author":"K Viala","year":"2010","unstructured":"Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):50\u20136.","journal-title":"J Peripher Nerv Syst"},{"issue":"12 Suppl 6","key":"386_CR4","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1212\/WNL.59.12_suppl_6.S7","volume":"59","author":"BC Kieseier","year":"2002","unstructured":"Kieseier BC, Dalakas MC, Hartung H-P. Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology. 2002;59(12 Suppl 6):S7\u201312.","journal-title":"Neurology"},{"issue":"3","key":"386_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jns.12344","volume":"24","author":"C Bunschoten","year":"2019","unstructured":"Bunschoten C, Blomkwist-Markens PH, Horemans A, van Doorn PA, Jacobs BC. Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019;24(3):253\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"12","key":"386_CR6","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1136\/jnnp.2007.114868","volume":"78","author":"A Chi\u00f2","year":"2007","unstructured":"Chi\u00f2 A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry. 2007;78(12):1349\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"386_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1529-8027.2010.00284.x","volume":"15","author":"KC Gorson","year":"2010","unstructured":"Gorson KC, van Schaik IN, Merkies ISJ, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010;15(4):326\u201333.","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"386_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1590\/0004-282X20130232","volume":"72","author":"PL dos Santos","year":"2014","unstructured":"dos Santos PL, Nogueira de Almeida-Ribeiro GA, Daoud Silva DM, Marques W Jr, Barreira AA. Chronic inflammatory demyelinating polyneuropathy: quality of life, sociodemographic profile and physical complaints. Arq Neuropsiquiatr. 2014;72(3):179\u201383.","journal-title":"Arq Neuropsiquiatr."},{"issue":"6","key":"386_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.mayocp.2018.03.026","volume":"93","author":"PJB Dyck","year":"2018","unstructured":"Dyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018;93(6):777\u201393.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"386_CR10","first-page":"368","volume":"59","author":"T Taylor","year":"2013","unstructured":"Taylor T. Chronic inflammatory demyelinating polyradiculoneuropathy: in a remote northern Ontario hospital. Can Fam Physician. 2013;59(4):368\u201371.","journal-title":"Can Fam Physician"},{"issue":"5","key":"386_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/WCO.0b013e328363bfa4","volume":"26","author":"F Eftimov","year":"2013","unstructured":"Eftimov F, van Schaik I. Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options. Curr Opin Neurol. 2013;26(5):496\u2013502.","journal-title":"Curr Opin Neurol"},{"key":"386_CR12","doi-asserted-by":"publisher","unstructured":"Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013;(12):CD001797. https:\/\/doi.org\/10.1002\/14651858.CD001797.pub3.","DOI":"10.1002\/14651858.CD001797.pub3"},{"issue":"9","key":"386_CR13","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s00415-018-8948-y","volume":"265","author":"GGA Van Lieverloo","year":"2018","unstructured":"Van Lieverloo GGA, Peric S, Doneddu PE, et al. A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol. 2018;265(9):2052\u20139.","journal-title":"J Neurol"},{"issue":"11","key":"386_CR14","first-page":"CD002062","volume":"11","author":"RA Hughes","year":"2017","unstructured":"Hughes RA, Mehndiratta MM, Rajabally YA. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;11(11):CD002062.","journal-title":"Cochrane Database Syst Rev."},{"issue":"3","key":"386_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"PY Van den Bergh","year":"2010","unstructured":"Van den Bergh PY, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014first revision. Eur J Neurol. 2010;17(3):356\u201363.","journal-title":"Eur J Neurol"},{"issue":"6","key":"386_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","volume":"11","author":"E Nobile-Orazio","year":"2012","unstructured":"Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012;11(6):493\u2013502.","journal-title":"Lancet Neurol"},{"issue":"1","key":"386_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ene.12245","volume":"21","author":"M Mahdi-Rogers","year":"2014","unstructured":"Mahdi-Rogers M, McCrone P, Hughes RA. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. Eur J Neurol. 2014;21(1):34\u20139.","journal-title":"Eur J Neurol"},{"key":"386_CR18","doi-asserted-by":"publisher","unstructured":"Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2003;(1):CD003280. https:\/\/doi.org\/10.1002\/14651858.CD003280.","DOI":"10.1002\/14651858.CD003280"},{"issue":"8","key":"386_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2165\/00003495-200969080-00004","volume":"69","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, van Doorn PA. Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs. 2009;69(8):987\u20131001.","journal-title":"Drugs"},{"issue":"8","key":"386_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM198602203140801","volume":"314","author":"PJ Dyck","year":"1986","unstructured":"Dyck PJ, Daube J, O\u2019Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314(8):461\u20135.","journal-title":"N Engl J Med"},{"issue":"Pt 4","key":"386_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","volume":"119","author":"AF Hahn","year":"1996","unstructured":"Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyradiculoneuropathy. A double-blind, sham-controlled, crossover study. Brain. 1996;119(Pt 4):1055\u201366.","journal-title":"Brain"},{"issue":"5","key":"386_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/mus.21433","volume":"40","author":"PD Donofrio","year":"2009","unstructured":"Donofrio PD, Berger A, Brannagan TH 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve. 2009;40(5):890\u2013900.","journal-title":"Muscle Nerve"},{"issue":"13","key":"386_CR23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","volume":"78","author":"HS Patwa","year":"2012","unstructured":"Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009\u201315.","journal-title":"Neurology"},{"key":"386_CR24","doi-asserted-by":"crossref","unstructured":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014First Revision. J Peripher Nerv Syst. 2010;15(1):1\u20139.","DOI":"10.1111\/j.1529-8027.2010.00245.x"},{"key":"386_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"P Van den Bergh","year":"2021","unstructured":"Van den Bergh P, van Doorn P, Hadden R, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. J Peripher Nerv Syst. 2021;26:242\u201368.","journal-title":"J Peripher Nerv Syst."},{"issue":"2","key":"386_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/jns5.12017","volume":"18","author":"JM L\u00e9ger","year":"2013","unstructured":"L\u00e9ger JM, De Bleecker JL, Sommer C, et al. Efficacy and safety of Privigen in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label phase III study (the PRIMA study). J Peripher Nerv Syst. 2013;18(2):130\u201340.","journal-title":"J Peripher Nerv Syst"},{"issue":"15","key":"386_CR27","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3181a0fd80","volume":"72","author":"ISJ Merkies","year":"2009","unstructured":"Merkies ISJ, Bril V, Dalakas MC, et al. Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE study. Neurology. 2009;72(15):1337\u201344.","journal-title":"Neurology"},{"issue":"2","key":"386_CR28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136\u201344.","journal-title":"Lancet Neurol"},{"issue":"6","key":"386_CR29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.thromres.2014.03.046","volume":"133","author":"E Ram\u00edrez","year":"2014","unstructured":"Ram\u00edrez E, Romero-Garrido JA, L\u00f3pez-Granados E, et al. Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. Thromb Res. 2014;133(6):1045\u201351.","journal-title":"Thromb Res"},{"issue":"4","key":"386_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/ene.13264","volume":"24","author":"A Totzeck","year":"2017","unstructured":"Totzeck A, Stettner M, Hagenacker T. Early platelet and leukocyte decline in patients with neuroinflammatory disorders after intravenous immunoglobulins. Eur J Neurol. 2017;24(4):638\u201344.","journal-title":"Eur J Neurol"},{"issue":"4","key":"386_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"EA Sekul","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121(4):259\u201362.","journal-title":"Ann Intern Med"},{"issue":"2","key":"386_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/NAN.0b013e31824237ce","volume":"35","author":"SS Dychter","year":"2012","unstructured":"Dychter SS, Gold DA, Carson D, Haller M. Intravenous therapy: a review of complications and economic considerations of peripheral access. J Infus Nurs. 2012;35(2):84\u201391.","journal-title":"J Infus Nurs"},{"issue":"5","key":"386_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","volume":"16","author":"T Harbo","year":"2009","unstructured":"Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009;16(5):631\u20138.","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"386_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/cei.12517","volume":"178","author":"SA Misbah","year":"2014","unstructured":"Misbah SA. Effective dosing strategies for therapeutic immunoglobulin: managing wear-off effects in antibody replacement to immunomodulation. Clin Exp Immunol. 2014;178(Suppl 1):70\u20131.","journal-title":"Clin Exp Immunol"},{"issue":"16 Suppl","key":"386_CR35","doi-asserted-by":"crossref","first-page":"P2.269","DOI":"10.1212\/WNL.86.16_supplement.P2.269","volume":"86","author":"J Allen","year":"2016","unstructured":"Allen J, Pasnoor M, Burns T, et al. Intravenous immunoglobulin (IVIg) treatment-related fluctuations in chronic inflammatory demyelinating polyneuropathy (CIDP) patients using daily grip strength measurements (GRIPPER): study design and progress update (P2.269). Neurology. 2016;86(16 Suppl):P2.269.","journal-title":"Neurology"},{"issue":"1","key":"386_CR36","first-page":"24","volume":"5","author":"B Slen","year":"2014","unstructured":"Slen B. Infused therapies: costs savings benefits through home infusion. Spec Pharm Times. 2014;5(1):24\u20135.","journal-title":"Spec Pharm Times."},{"issue":"a","key":"386_CR37","first-page":"e41","volume":"6","author":"R Luthra","year":"2014","unstructured":"Luthra R, Quimbo R, Iver R, Luo M. An analysis of intravenous immunoglobulin site of care: home vs outpatient hospital. Am J Pharm Benefits. 2014;6(a):e41\u20139.","journal-title":"Am J Pharm Benefits."},{"issue":"1","key":"386_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10875-006-8905-x","volume":"26","author":"U Nicolay","year":"2006","unstructured":"Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26(1):65\u201372.","journal-title":"J Clin Immunol"},{"issue":"1","key":"386_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","volume":"17","author":"IN van Schaik","year":"2018","unstructured":"van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35\u201346.","journal-title":"Lancet Neurol"},{"issue":"1","key":"386_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/ene.14056","volume":"27","author":"H-P Hartung","year":"2020","unstructured":"Hartung H-P, Mallick R, Bril V, et al. Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. Eur J Neurol. 2020;27(1):196\u2013203.","journal-title":"Eur J Neurol"},{"key":"386_CR41","unstructured":"Merkies ISJ, Mallick R, Haudrich A, et al. Impact of CIDP on daily activity and participation: I-RODS analysis from a US patient survey. In: Presented at the Annual Meeting of the Peripheral Nerve Society; June 2018; Baltimore, MD."},{"issue":"5","key":"386_CR42","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000590","volume":"6","author":"IN van Schaik","year":"2019","unstructured":"van Schaik IN, Mielke O, Bril V, et al. Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP PATH extension study. Neurol Neuroimmunol Neuroinflamm. 2019;6(5): e590.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"7","key":"386_CR43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/jnnp-2014-310280","volume":"87","author":"D Cocito","year":"2016","unstructured":"Cocito D, Merola A, Romagnolo A, et al. Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response? J Neurol Neurosurg Psychiatry. 2016;87(7):791\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"386_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/1756285614563056","volume":"8","author":"RD Hadden","year":"2015","unstructured":"Hadden RD, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction. Ther Adv Neurol Disord. 2015;8(1):14\u20139.","journal-title":"Ther Adv Neurol Disord"},{"key":"386_CR45","unstructured":"Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions Version 4.1. 2020. https:\/\/www.amcp.org\/sites\/default\/files\/2019-12\/AMCP_Format%204.1_1219_final.pdf. Accessed 5 May 2022."},{"issue":"1","key":"386_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5\u201314.","journal-title":"Value Health."},{"key":"386_CR47","unstructured":"Red Book, IBM Micromedex. 2021: Copyright IBM Corporation."},{"key":"386_CR48","unstructured":"Academy of Managed Care Pharmacy. AMCP guide to pharmaceutical payment methods, 2013 update. Version 3.0. Published April 2013."},{"key":"386_CR49","unstructured":"Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015\u20132018. National Center for Health Statistics. Vital Health Stat., series 3, number 46; 2021, p. 1\u2013441."},{"key":"386_CR50","unstructured":"Gamunex-C prescribing information. Research Triangle Park, NC: Grifols Therapeutics LLC; 2017."},{"key":"386_CR51","doi-asserted-by":"crossref","unstructured":"GBS\/CIPD Foundation patient reported outcomes and treatment survey 2018. 2018 Peripheral Nerve Society Annual Meeting 21\u201325 July, 2018, Baltimore, Maryland. J Peripher Nerv Syst. 2018;23(4):249\u2013405.","DOI":"10.1111\/jns.12290"},{"issue":"2","key":"386_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/00001786-199812000-00010","volume":"13","author":"AJ Barton","year":"1998","unstructured":"Barton AJ, Danek G, Johns P, Coons M. Improving patient outcomes through CQI: vascular access planning. J Nurs Care Qual. 1998;13(2):77\u201385.","journal-title":"J Nurs Care Qual"},{"issue":"3 Suppl","key":"386_CR53","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/00129804-200505001-00005","volume":"28","author":"K Kokotis","year":"2005","unstructured":"Kokotis K. Cost containment and infusion services. J Infus Nurs. 2005;28(3 Suppl):S22\u201332.","journal-title":"J Infus Nurs"},{"issue":"2","key":"386_CR54","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/archsurg.136.2.229","volume":"136","author":"JB Dimick","year":"2001","unstructured":"Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg. 2001;136(2):229\u201334.","journal-title":"Arch Surg"},{"key":"386_CR55","unstructured":"Hizentra prescribing information. Kanakee, IL: CSL Behring; 2022."},{"key":"386_CR56","unstructured":"Find-a-code. CPT 98960. https:\/\/www.findacode.com\/cpt\/98960-cpt-code.html. Accessed 4 Feb 2021."},{"key":"386_CR57","unstructured":"United States Bureau of Labor Statistics. Economic news release. Table B-3: Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. https:\/\/www.bls.gov\/news.release\/empsit.t19.htm. Accessed 5 May 2022."},{"issue":"4","key":"386_CR58","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/00129804-200407000-00008","volume":"27","author":"J Pierce","year":"2004","unstructured":"Pierce J, Baker J. A nursing process model: quantifying infusion therapy resource consumption. J Inf Nurs. 2004;27(4):232\u201344.","journal-title":"J Inf Nurs."},{"key":"386_CR59","unstructured":"Agency for Healthcare Research and Quality (AHRQ). Healthcare Cost and Utilization Project (HCUP). https:\/\/hcupnet.ahrq.gov\/#setup. Accessed 5 May 2022."},{"issue":"9","key":"386_CR60","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.4065\/81.9.1159","volume":"81","author":"D Maki","year":"2006","unstructured":"Maki D, Kluger D, Crnich C, et al. Risk of bloodstream infection in adults with different intra-vascular devices: a systematic review of 200 published prospective studies. Mayo Clinic Proc. 2006;81(9):1159\u201371.","journal-title":"Mayo Clinic Proc"},{"issue":"8","key":"386_CR61","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.NAJ.0000282299.03441.c7","volume":"107","author":"L Hadaway","year":"2007","unstructured":"Hadaway L. Infiltration and extravasation: preventing a complication of IV catheterization. Am J Nurs. 2007;107(8):64\u201372.","journal-title":"Am J Nurs."},{"key":"386_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.thromres.2015.11.033","volume":"137","author":"S Grosse","year":"2016","unstructured":"Grosse S, Nelson R, Nyarko K, et al. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res. 2016;137:3\u201310.","journal-title":"Thromb Res"},{"issue":"21","key":"386_CR63","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1182\/blood.V124.21.2884.2884","volume":"124","author":"V Bharath","year":"2014","unstructured":"Bharath V, Eckert K, Kang M, et al. Incidence and natural history of IVIG-induced aseptic meningitis: a retrospective review at a single tertiary care centre. Blood. 2014;124(21):2884.","journal-title":"Blood"},{"key":"386_CR64","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1537-2995.2008.01721.x","volume":"48","author":"Z Daw","year":"2008","unstructured":"Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion. 2008;48:1598\u2013601.","journal-title":"Transfusion"},{"key":"386_CR65","unstructured":"Weiss AJ, Pickens G, Roemer M. Methods for calculating patient travel distance to hospital in HCUP data. HCUP Methods Series Report # 2021-02 Online. December 6, 2021. www.hcup-us.ahrq.gov\/reports\/methods\/methods.jsp. Accessed 14 Oct 2022."},{"issue":"5","key":"386_CR66","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1200\/OP.20.00065","volume":"16","author":"N Premnath","year":"2020","unstructured":"Premnath N, Grewal U, Gupta A. Park the parking. JCO Oncol Pract. 2020;16(5):215\u20137.","journal-title":"JCO Oncol Pract."},{"issue":"Suppl 1","key":"386_CR67","first-page":"612","volume":"29","author":"M Kleman","year":"2022","unstructured":"Kleman M, Myren K, Tursunova S, et al. Impact of generalised myasthenia gravis on activities of daily living and employment for patients and caregivers. Eur J Neurol. 2022;29(Suppl 1):612.","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"386_CR68","first-page":"S245","volume":"9","author":"S Jacob","year":"2022","unstructured":"Jacob S, Dewilde S, Qi C, et al. Productivity losses for generalized myasthenia gravis patients and their caregivers: association with disease severity. J Neuromuscul Dis. 2022;9(Suppl 1):S245\u20136.","journal-title":"J Neuromuscul Dis."},{"issue":"3","key":"386_CR69","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1529-8027.2010.00274.x","volume":"15","author":"IS Merkies","year":"2010","unstructured":"Merkies IS, Hughes RA, Donofrio P, et al. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study. J Peripher Nerv Syst. 2010;15(3):208\u201315.","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"386_CR70","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/jnnp.66.5.677","volume":"66","author":"MP Lunn","year":"1999","unstructured":"Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry. 1999;66(5):677\u201380.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"386_CR71","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","volume":"17","author":"D Cocito","year":"2010","unstructured":"Cocito D, Paolasso I, Antonini G, et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(2):289\u201394.","journal-title":"Eur J Neurol"},{"issue":"4","key":"386_CR72","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","volume":"114","author":"A Gardulf","year":"2004","unstructured":"Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114(4):936\u201342.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"386_CR73","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s10875-018-0562-3","volume":"38","author":"R Mallick","year":"2018","unstructured":"Mallick R, Jolles S, Kanegane H, Agbor-Tarh D, Rojavin M. Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a pooled analysis of six Hizentra\u00ae studies. J Clin Immunol. 2018;38(8):886\u201397.","journal-title":"J Clin Immunol"},{"key":"386_CR74","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018;9:1299.","journal-title":"Front Immunol"},{"issue":"9","key":"386_CR75","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1377\/hlthaff.2013.1327","volume":"33","author":"DU Himmelstein","year":"2014","unstructured":"Himmelstein DU, Jun M, Busse R, et al. A comparison of hospital administrative costs in eight nations: US costs exceed all others by far. Health Aff (Millwood). 2014;33(9):1586\u201394.","journal-title":"Health Aff (Millwood)."},{"issue":"6","key":"386_CR76","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1002\/art.39079","volume":"67","author":"J Yazdany","year":"2015","unstructured":"Yazdany J, Dudley RA, Chen R, Lin GA, Tseng CW. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D. Arthritis Rheumatol. 2015;67(6):1474\u201380.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"386_CR77","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.clinthera.2017.06.007","volume":"39","author":"J Schmeir","year":"2017","unstructured":"Schmeir J, Ogden K, Nickman N, et al. Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting. Clin Ther. 2017;39(8):1600\u201317.","journal-title":"Clin Ther"},{"issue":"2","key":"386_CR78","first-page":"96","volume":"18","author":"TM Windegger","year":"2020","unstructured":"Windegger TM, Nghiem S, Nguyen KH, Fung YL, Scuffham PA, et al. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia. Blood Transfus. 2020;18(2):96\u2013105.","journal-title":"Blood Transfus"},{"issue":"2","key":"386_CR79","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1017\/S0266462300006942","volume":"11","author":"A Gardulf","year":"1995","unstructured":"Gardulf A, Jonsson G. A comparison of the patient-borne costs of therapy with gamma globulin given at the hospital or at home. Int J Technol Assess Health Care. 1995;11(2):345\u201353.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"386_CR80","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s10198-004-0250-5","volume":"6","author":"B H\u00f6gy","year":"2005","unstructured":"H\u00f6gy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6(1):24\u20139.","journal-title":"Eur J Health Econ."},{"key":"386_CR81","unstructured":"Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. University of Birmingham. 2005. https:\/\/www.birmingham.ac.uk\/Documents\/college-mds\/haps\/projects\/WMHTAC\/REPreports\/2005\/IgRT.pdf. Accessed 12 Oct 2020."},{"issue":"1","key":"386_CR82","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-3148.2012.01201.x","volume":"23","author":"A Martin","year":"2013","unstructured":"Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55\u201360. https:\/\/doi.org\/10.1111\/j.1365-3148.2012.01201.x.","journal-title":"Transfus Med"},{"issue":"2","key":"386_CR83","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2249.2009.04079.x","volume":"160","author":"J Beaut\u00e9","year":"2010","unstructured":"Beaut\u00e9 J, Levy P, Millet V, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240\u20135.","journal-title":"Clin Exp Immunol"},{"key":"386_CR84","unstructured":"Flaherty L. Covid infusion therapy shifts to the home. https:\/\/www.hmenews.com\/article\/covid-infusion-therapy-shifts-to-the-home. Accessed 29 Apr 2022."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00386-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T18:37:40Z","timestamp":1728844660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00386-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00386-2","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"3 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by CSL Behring.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rajiv Mallick is an employee of CSL Behring and holds stock options. Rashad Carlton and Joris Van Stiphout are employees of Xcenda, which received funding from CSL Behring for this analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data for the model were obtained from a variety of sources, including published studies, publicly available costs and databases, and assumptions as necessary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"As this was an economic analysis that did not use any identifiable patient data, no ethics approval was required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"An unlocked version of the model has been provided as ESM. The input parameters specific to the US-approved labeling for Hizentra, including dosing and relapse parameters, are not modifiable. The VBA coding is proprietary to the model developers and is not publicly available.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: RM, RC, and JVS. Methodology: RM, RC, and JVS. Formal analysis: RM, RC, and JVS. Writing, review, and editing: RM, RC, and JVS.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}